EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection - Epidemiology Forecast to 2022

Publisher Name :
Date: 15-Nov-2013
No. of pages: 54

Urinary tract infections (UTIs) are among the most common bacterial infections acquired in hospitals and in the community setting. A UTI can occur when daily living activities and medical interventions aid in the movement of bacteria into the urethra; however, bacterial colonization does not always lead to the development of UTI symptoms. Although UTIs can be caused by bacteria, viruses, or fungi, gram-negative bacteria are the pathogens most frequently associated with UTIs. Gram-negative bacteria have become increasingly resistant to individual antimicrobials, and of particular concern, is the emergence of multidrug-resistant activity in these organisms. Although there has been little change in the predominant causative pathogens in the past few decades, individual pathogen frequency and resistance patterns of gram-negative pathogens vary considerably between settings, countries, and continents.

According to GlobalData's forecast, the number of incident cases of UTI will increase in the US during the forecast period. The largest number of cases will be classified as community-acquired and occur in women =80 years of age. The 5EU will see a slight increase in the number of healthcare-associated incident cases of UTI during the forecast period, with the highest number of cases occurring among women in Germany, and among those ages 70-79 years. Japan is forecast to see a large increase in the number of incident cases of UTI occurring during the forecast period in intensive care units, with the greatest number of cases occurring among women and those =80 years.

A major strength of this analysis is that GlobalData epidemiologists used country-specific sources for each market in the analysis and were able to obtain country-specific national surveillance data for the 5EU and Japan. The use of country-specific sources is especially important for antimicrobial resistance data as the rates of resistance have been found to vary considerably between countries. Additionally, because resistance rates have changed over time, GlobalData's use of recent sources for resistance rates ensures that the estimates for the number of resistant cases of UTI reflect the most current situation in each market.

Scope


  • The Gram-Negative Bacterial Urinary Tract Infection (UTI) EpiCast Report provides an overview of the risk factors and global trends of UTI in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of UTI incident cases segmented by age (0-85 years and older), sex, causative pathogen (Escherichia coli, Klebsiella, Pseudomonas aeruginosa, Proteus, and Acinetobacter), multidrug resistance, and carbapenem resistance in these markets.

  • The UTI epidemiology report is written and developed by Mastersand PhD-level epidemiologists.

  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.


Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global UTI market.

  • Quantify patient populations in the global UTI market to improve product design, pricing, and launch plans.

  • Organize sales and marketing efforts by identifying the sex, age groups, pathogens, and antibiotic resistance patterns that present the best opportunities for UTI therapeutics in each of the markets covered.

EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection - Epidemiology Forecast to 2022

Table Of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8

3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.2.1 Women are more likely than men to experience UTI at all ages 11
3.2.2 The risk of developing UTI increases 3%-6% per day of catheterization 11
3.2.3 Older age is a major risk factor for UTI 12
3.2.4 Sexual intercourse can increase the relative odds of UTI in women by a factor as high as 60 13
3.2.5 Diabetic individuals have an increased incidence of UTI and increased associated complications 13
3.3 Forecast Methodology 14
3.3.1 Sources Used 15
3.3.2 Forecast Assumptions and Methods 19
3.4 Epidemiological Forecast for UTI (2012-2022) 24
3.4.1 US 24
3.4.2 5EU 29
3.4.3 Japan 36
3.5 Discussion 41
3.5.1 Conclusions on Epidemiological Trends 41
3.5.2 Limitations of the Analysis 42
3.5.3 Strengths of the Analysis 43

4 Appendix 44
4.1 Bibliography 44
4.2 About the Authors 49
4.2.1 Epidemiologists 49
4.2.2 Reviewers 49
4.2.3 Franka des Vignes, PhD, Global Director of Epidemiology and Health Policy 51
4.2.4 Bonnie Bain, PhD, Global Head of Healthcare 51
4.3 About GlobalData 52
4.4 About EpiCast 52
4.5 Disclaimer 53

List of Tables

Table 1: Risk Factors for Urinary Tract Infection 11
Table 2: Sources of Incidence Data Used in the Epidemiology Forecast 14
Table 3: US, Incident Cases of Gram-Negative UTI, N, by Site of Acquisition, Select Years, 2012-2022 25
Table 4: US, Incident Cases of Gram-Negative UTI, by Age and Site of Acquisition, N (Row %), 2012 26
Table 5: US, Incident Cases of Gram-Negative UTI, by Sex and Site of Acquisition, N (Row %), 2012 27
Table 6: US, Incident Cases of Gram-Negative UTI, by Pathogen and Site of Acquisition, N (Column %), 2012 28
Table 7: US, Incident Cases of Gram-Negative UTI, by Pathogen and Multidrug* and Carbapenem? Resistance, N, Percentage of Pathogen-Specific Cases, 2012 29
Table 8: 5EU, Incident Cases of UTI, N, Select Years, 2012-2022 30
Table 9: 5EU, Incident Cases of UTI, by Age, N (Row %), 2012 31
Table 10: 5EU, Incident Cases of UTI, by Sex, N (Row %), 2012 32
Table 11: 5EU, Incident Cases of UTI, by Pathogen, N (Percentage of Total Country-Specific Cases Caused by Pathogen), 2012 33
Table 12: 5EU, Incident Cases of UTI, by Pathogen and Multidrug and Carbapenem Resistance, N, and Percentage of Pathogen-Specific Cases, 2012 35
Table 13: Japan, Incident Cases of UTI, N, Select Years, 2012-2022 36
Table 14: Japan, Incident Cases of UTI, by Age, N (Row %), 2012 37
Table 15: Japan, Incident Cases of UTI, by Sex, N (Row %), 2012 38
Table 16: Japan, Incident Cases of UTI, by Pathogen, N (Percentage of Total Country-Specific Cases Caused by Pathogen), 2012 39
Table 17: Japan, Incident Cases of UTI, by Pathogen and Antibiotic, Number of Antibiotic-Resistant Cases (N) and Percentage of Antibiotic-Resistant Pathogen-Specific Cases (%), 2012 40

List of Figures

Figure 1: US, Incident Cases of Gram-Negative UTI, N, by Site of Acquisition, Select Years, 2012-2022 25
Figure 2: US, Incident Cases of Gram-Negative UTI, by Age and Site of Acquisition, N, 2012 26
Figure 3: US, Incident Cases of Gram-Negative UTI, by Sex, N, 2012 27
Figure 4: US, Incident Cases of Gram-Negative UTI, by Pathogen and Site of Acquisition, N, 2012 28
Figure 5: 5EU, Incident Cases of UTI, N, Select Years, 2012-2022 30
Figure 6: 5EU, Incident Cases of UTI, by Age, N, 2012 31
Figure 7: 5EU, Incident Cases of UTI, by Sex, N, 2012 32
Figure 8: 5EU, Incident Cases of UTI, by Pathogen, N, 2012 34
Figure 9: Japan, Incident Cases of UTI, N, Select Years, 2012-2022 36
Figure 10: Japan, Incident Cases of UTI, by Age, N, 2012 37
Figure 11: Japan, Incident Cases of UTI, by Sex, N, 2012 38
Figure 12: Japan, Incident Cases of UTI, by Pathogen, N, 2012 39

  • Global Genitourinary Drugs Industry 2016 Market Research Report
    Published: 28-Apr-2016        Price: US 2800 Onwards        Pages: 159
    The Global Genitourinary Drugs Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Genitourinary Drugs industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Genitourinary Drugs market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development st......
  • Overactive Bladder - Pipeline Review, H1 2016
    Published: 20-Apr-2016        Price: US 2000 Onwards        Pages: 114
    Global Markets Direct's, ‘Overactive Bladder - Pipeline Review, H1 2016', provides an overview of the Overactive Bladder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Overactive Bladder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete res......
  • Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology and Market Forecast-2020
    Published: 01-Apr-2016        Price: US 4950 Onwards        Pages: 70
    Note*: This report requires 5-10 business days to complete. DelveInsight's Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology and Market Forecast-2020" Reports provides an overview of the disease and global market trends of the %Indication"% for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Benign prostatic ......
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2016
    Published: 30-Mar-2016        Price: US 2000 Onwards        Pages: 100
    Global Markets Direct's, ‘Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2016', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The repor......
  • Toviaz -Drug Insights, 2016
    Published: 31-Jan-2016        Price: US 1000 Onwards        Pages: 35
    DelveInsight Drug Report, "Toviaz- Drug Insights, 2016" highlights the Toviaz marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsight's report covers the Global Market Assessment of the Toviaz covering the total sales estimation and also provides the Toviaz sales performance during the historical period and forecast period to 2018. DelveInsight's Report also covers the detailed clinical assessment of Toviaz, patents information and exclusivity......
  • Global and Chinese Mirabegron Industry, 2016 Market Research Report
    Published: 07-Jan-2016        Price: US 2800 Onwards        Pages: 150
    The 'Global and Chinese Mirabegron Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Mirabegron industry with a focus on the Chinese market. The report provides key statistics on the market status of the Mirabegron manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides a basic overview of the industry including its definition, applicati......
  • Global and Chinese Fesoterodine Fumarate Industry, 2016 Market Research Report
    Published: 07-Jan-2016        Price: US 2800 Onwards        Pages: 150
    The 'Global and Chinese Fesoterodine Fumarate Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Fesoterodine Fumarate industry with a focus on the Chinese market. The report provides key statistics on the market status of the Fesoterodine Fumarate manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides a basic overview of the industry in......
  • Dysuria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Jan-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Dysuria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Dysuria Report is to understand the market and pipeline status of the drugs around the Dysuria to explore the generic development opportunities, licensing opportunities and t......
  • Fistula-Pipeline Insights, 2016
    Published: 01-Jan-2016        Price: US 1250 Onwards        Pages: 60
    SUMMARY DelveInsight's, " Fistula-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Fistula. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisition......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs